Top

Current Hypertension Reports

Published in:

01-09-2020 | Coronavirus | Hypertension and the Heart (B Upadhya, Section Editor)

Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses

Authors: Eleni Gavriilaki, Panagiota Anyfanti, Maria Gavriilaki, Antonios Lazaridis, Stella Douma, Eugenia Gkaliagkousi

Published in: Current Hypertension Reports | Issue 9/2020

Abstract

Purpose of Review

To review current literature on endothelial dysfunction with previous coronaviruses, and present available data on the role of endothelial dysfunction in coronavirus disease-2019 (COVID-19) infection in terms of pathophysiology and clinical phenotype

Recent Findings

Recent evidence suggests that signs and symptoms of severe COVID-19 infection resemble the clinical phenotype of endothelial dysfunction, implicating mutual pathophysiological pathways. Dysfunction of endothelial cells is believed to mediate a variety of viral infections, including those caused by previous coronaviruses. Experience from previous coronaviruses has triggered hypotheses on the role of endothelial dysfunction in the pathophysiology of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which are currently being tested in preclinical and clinical studies.

Summary

Endothelial dysfunction is the common denominator of multiple clinical aspects of severe COVID-19 infection that have been problematic for treating physicians. Given the global impact of this pandemic, better understanding of the pathophysiology could significantly affect management of patients.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5.CrossRefPubMedPubMedCentral

Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antivir Res. 2012;93(1):2–15. https://doi.org/10.1016/j.antiviral.2011.10.019.CrossRefPubMed

•• Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VE, Meijers JC, et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012;84(10):1680–96. https://doi.org/10.1002/jmv.23354The dysregulation of the coagulation cascade is a prominent finding in viral infections.CrossRefPubMedPubMedCentral

• Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69. https://doi.org/10.7150/ijbs.7502This report described the main endothelial abnormalities that are typically encountered in various human diseases including cancer, diabetes mellitus, atherosclerosis, and viral infections.CrossRefPubMedPubMedCentral

Michiels C. Endothelial cell functions. J Cell Physiol. 2003;196(3):430–43. https://doi.org/10.1002/jcp.10333.CrossRefPubMed

•• Godo S, Shimokawa H. Endothelial functions. Arterioscler Thromb Vasc Biol. 2017;37(9):e108–e14. https://doi.org/10.1161/ATVBAHA.117.309813Εndothelial functions in health and disease are summarized in this well-written informative report.CrossRefPubMed

Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res. 2007;101(7):654–62. https://doi.org/10.1161/CIRCRESAHA.107.158410.CrossRefPubMed

Fleming I, Bauersachs J, Busse R. Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J Vasc Res. 1997;34(3):165–74. https://doi.org/10.1159/000159220.CrossRefPubMed

Gkaliagkousi E, Douma S, Zamboulis C, Ferro A. Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens. 2009;27(12):2310–20. https://doi.org/10.1097/HJH.0b013e328330e89a.CrossRefPubMed

10.

List BM, Klosch B, Volker C, Gorren AC, Sessa WC, Werner ER, et al. Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization. Biochem J. 1997;323(Pt 1):159–65. https://doi.org/10.1042/bj3230159.CrossRefPubMedPubMedCentral

11.

Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ, Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension. 2006;47(1):87–94. https://doi.org/10.1161/01.HYP.0000196735.85398.0e.CrossRefPubMed

12.

Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vasc Pharmacol. 2018;100:1–19. https://doi.org/10.1016/j.vph.2017.05.005.CrossRef

13.

Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep. 2015;17(11):85. https://doi.org/10.1007/s11906-015-0596-3.CrossRefPubMed

14.

Gkaliagkousi E, Gavriilaki E, Vasileiadis I, Nikolaidou B, Yiannaki E, Lazaridis A, et al. Endothelial microvesicles circulating in peripheral and coronary circulation are associated with central blood pressure in coronary artery disease. Am J Hypertens. 2019;32(12):1199–205. https://doi.org/10.1093/ajh/hpz116.CrossRefPubMed

15.

• Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Nikolaidou B, Anyfanti P, Koletsos N, et al. Asymmetric dimethylarginine levels are associated with augmentation index across naive untreated patients with different hypertension phenotypes. J Clin Hypertens (Greenwich). 2018;20(4):680–5. https://doi.org/10.1111/jch.13237In this review the mechanisms, clinical significance and methods for the assessment of endothelial dysfunction in patients with essential hypertension are discussed.CrossRef

16.

Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2008;133(1):4–12. https://doi.org/10.1016/j.virusres.2007.01.022.CrossRefPubMed

17.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. https://doi.org/10.1002/path.1570.CrossRefPubMedPubMedCentral

18.

Yang YH, Huang YH, Chuang YH, Peng CM, Wang LC, Lin YT, et al. Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Virol. 2005;77(1):1–7. https://doi.org/10.1002/jmv.20407.CrossRefPubMedPubMedCentral

19.

Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–9. https://doi.org/10.1002/path.1440.CrossRefPubMedPubMedCentral

20.

Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern Pathol: an official journal of the United States and Canadian Academy of Pathology, Inc. 2005;18(1):1–10. https://doi.org/10.1038/modpathol.3800247.CrossRef

21.

Xiang-Hua Y, Le-Min W, Ai-Bin L, Zhu G, Riquan L, Xu-You Z, et al. Severe acute respiratory syndrome and venous thromboembolism in multiple organs. Am J Respir Crit Care Med. 2010;182(3):436–7. https://doi.org/10.1164/ajrccm.182.3.436.CrossRefPubMed

22.

Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol : the official publication of the Pan American Society for Clinical Virology. 2020;127:104362. https://doi.org/10.1016/j.jcv.2020.104362.CrossRef

23.

Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185–95. https://doi.org/10.1002/path.4454.CrossRefPubMed

24.

Gralinski LE, Bankhead A 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013;4(4):e00271–13. https://doi.org/10.1128/mBio.00271-13.CrossRefPubMedPubMedCentral

25.

Tang BS, Chan KH, Cheng VC, Woo PC, Lau SK, Lam CC, et al. Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by severe acute respiratory syndrome coronavirus and human coronavirus 229E. J Virol. 2005;79(10):6180–93. https://doi.org/10.1128/JVI.79.10.6180-6193.2005.CrossRefPubMedPubMedCentral

26.

Han M, Yan W, Huang Y, Yao H, Wang Z, Xi D, et al. The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. J Biochem. 2008;144(1):51–62. https://doi.org/10.1093/jb/mvn042.CrossRefPubMed

27.

Ng LF, Hibberd ML, Ooi EE, Tang KF, Neo SY, Tan J, et al. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis. 2004;4:34. https://doi.org/10.1186/1471-2334-4-34.CrossRefPubMedPubMedCentral

28.

Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326(7403):1358–62. https://doi.org/10.1136/bmj.326.7403.1358.CrossRefPubMedPubMedCentral

29.

• Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–94. https://doi.org/10.1056/NEJMoa030685A report of clinical, laboratory, and radiologic features of severe acute respiratory syndrome (SARS) outbreak in Hong Kong back in 2003.CrossRefPubMed

30.

Yang M, Ng MH, Li CK, Chan PK, Liu C, Ye JY, et al. Thrombopoietin levels increased in patients with severe acute respiratory syndrome. Thromb Res. 2008;122(4):473–7. https://doi.org/10.1016/j.thromres.2007.12.021.CrossRefPubMedPubMedCentral

31.

Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, et al. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. Thromb Haemost. 2006;96(1):100–1. https://doi.org/10.1160/TH05-12-0827.CrossRefPubMed

32.

Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA : the journal of the American Medical Association. 2003;290(3):374–80. https://doi.org/10.1001/jama.290.3.374.CrossRefPubMed

33.

Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–31. https://doi.org/10.1007/s00415-004-0519-8.CrossRefPubMedPubMedCentral

34.

Sun W, Wang BL, Liu BL, Zhao FC, Shi ZC, Guo WS, et al. Osteonecrosis in patients after severe acute respiratory syndrome (SARS): possible role of anticardiolipin antibodies. J Clin Rheumatol : practical reports on rheumatic & musculoskeletal diseases. 2010;16(2):61–3. https://doi.org/10.1097/RHU.0b013e3181cf3464.CrossRef

35.

Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361(9371):1773–8. https://doi.org/10.1016/s0140-6736(03)13413-7.CrossRefPubMedPubMedCentral

36.

Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, Leo YS, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med. 2004;128(2):195–204. https://doi.org/10.1043/1543-2165(2004)128<195:AODDTS>2.0.CO;2.CrossRefPubMed

37.

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–4. https://doi.org/10.1038/s41577-020-0320-7.CrossRefPubMed

38.

Gavriilaki E, Touloumenidou T, Sakellari I, Batsis I, Mallouri D, Psomopoulos F, et al. Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2020;120(4):638–46. https://doi.org/10.1055/s-0040-1702225.CrossRefPubMed

39.

Gavriilaki E, Chrysanthopoulou A, Sakellari I, Batsis I, Mallouri D, Touloumenidou T, et al. Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2019;119(9):1433–40. https://doi.org/10.1055/s-0039-1692721.CrossRefPubMed

40.

Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239–51. https://doi.org/10.1182/blood.2019003863.CrossRefPubMedPubMedCentral

41.

Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest. 2020;130(5):2152–63. https://doi.org/10.1172/JCI136094.CrossRefPubMedPubMedCentral

42.

Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–7. https://doi.org/10.26355/eurrev_202004_20875.CrossRefPubMed

43.

Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450. https://doi.org/10.1016/j.clim.2020.108450.CrossRefPubMedPubMedCentral

44.

Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–100. https://doi.org/10.1093/cvr/cvaa078.CrossRefPubMed

45.

Wan Y, Shang J, Graham R, Baric RS, Li F. receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–0. https://doi.org/10.1128/JVI.00127-20.CrossRefPubMedPubMedCentral

46.

Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75. https://doi.org/10.1128/JVI.00737-08.CrossRefPubMedPubMedCentral

47.

Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–8. https://doi.org/10.1021/acschemneuro.0c00122.CrossRefPubMed

48.

Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14277.

49.

Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92:699–702. https://doi.org/10.1002/jmv.25915.CrossRefPubMed

50.

Pappas G, Christou L, Akritidis N, Tsianos EV. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2006;12(9):823–5. https://doi.org/10.1111/j.1469-0691.2006.01442.x.CrossRef

51.

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020:201187. https://doi.org/10.1148/radiol.2020201187.

52.

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55–8. https://doi.org/10.1016/j.ijid.2020.03.062.CrossRefPubMedPubMedCentral

53.

Novi G, Rossi T, Pedemonte E, Saitta L, Rolla C, Roccatagliata L, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurology - Neuroimmunology Neuroinflammation. 2020;7(5):e797. https://doi.org/10.1212/nxi.0000000000000797.CrossRef

54.

• Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020;189(6):e227–e30. https://doi.org/10.1111/bjh.16783This perspective article describes similarities of severe COVID with complement-mediated thrombotic microangiopathy.CrossRefPubMed

55.

• Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res: the journal of laboratory and clinical medicine. 2020. https://doi.org/10.1016/j.trsl.2020.04.007A case-series study describing a possible pathophysiologic mechanism of severe COVID-19 infection unravelled the catastrophic microvascular injury syndrome mediated by complement cascade.

56.

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–8. https://doi.org/10.1056/NEJMoa2015432.CrossRefPubMedPubMedCentral

57.

Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020

58.

•• Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020. https://doi.org/10.1111/his.14134This autopsy study revealed generalized thrombotic microangiopathy and endothelial dysfunction in COVID-19 patients.

59.

Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020. https://doi.org/10.7326/M20-2003.

60.

Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7. https://doi.org/10.1016/j.thromres.2020.04.013.CrossRefPubMedPubMedCentral

61.

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421–4. https://doi.org/10.1111/jth.14830.CrossRefPubMed

62.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost : JTH. 2020;18:1094–9. https://doi.org/10.1111/jth.14817.CrossRefPubMed

63.

Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047430.

64.

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14888.

65.

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–98. https://doi.org/10.1007/s00134-020-06062-x.CrossRefPubMedPubMedCentral

66.

Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost : JTH. 2020;18:1743–6. https://doi.org/10.1111/jth.14869.CrossRefPubMed

67.

Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan. Italy Thrombosis Research. 2020;191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024.CrossRefPubMed

68.

Artifoni M, Danic G, Gautier G, Gicquel P, Boutoille D, Raffi F, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50:211–6. https://doi.org/10.1007/s11239-020-02146-z.CrossRefPubMedPubMedCentral

69.

Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50:72–81. https://doi.org/10.1007/s11239-020-02138-z.CrossRefPubMedPubMedCentral

70.

• Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. n/a(n/a). https://doi.org/10.1111/jth.14929. This consensus provides practical guidance for the diagnosis, thromboprophylaxis strategies, and treatment of venous thromboembolism in hospitalized patients with suspected or confirmed COVID-19 infection.

71.

Andrea V, Gianluca F, Rodolfo P, Paolo T, Alessandro P, Mauro G. Unheralded lower limb threatening ischemia in a COVID-19 patient. Int J Infect Diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;96:590–2. https://doi.org/10.1016/j.ijid.2020.05.060.CrossRef

72.

Kaur P, Qaqa F, Ramahi A, Shamoon Y, Singhal M, Shamoon F, et al. Acute upper limb ischemia in a patient with COVID-19. Hematol/Oncol Stem Cell Ther. 2020. https://doi.org/10.1016/j.hemonc.2020.05.001.

73.

Perini P, Nabulsi B, Massoni CB, Azzarone M, Freyrie A. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet. 2020;395(10236):1546. https://doi.org/10.1016/S0140-6736(20)31051-5.CrossRefPubMedPubMedCentral

74.

Fan BE, Chia YW, Sum CLL, Kuperan P, Chan SSW, Ling LM, et al. Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia. J Thromb Thrombolysis. 2020. https://doi.org/10.1007/s11239-020-02165-w.

75.

Bellosta R, Luzzani L, Natalini G, Pegorer MA, Attisani L, Cossu LG, et al. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg. 2020. https://doi.org/10.1016/j.jvs.2020.04.483.

76.

Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020;14(3):247–50. https://doi.org/10.1016/j.dsx.2020.03.013.CrossRef

77.

• Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.0950This cohort study associated cardiac injury with higher risk of inhospital mortality in COVID-19 patients.

78.

Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020. https://doi.org/10.1016/j.pcad.2020.03.001.

79.

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–55. https://doi.org/10.1161/CIRCULATIONAHA.120.046941.CrossRefPubMed

80.

Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region-case series. N Engl J Med. 2020;382(21):2012–22. https://doi.org/10.1056/NEJMoa2004500.CrossRefPubMed

81.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1017.

82.

•• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5The first cohort study from Wuhan describing COVID-19 patient baseline characteristics, clinical manifestations, and mortality rate.CrossRefPubMedPubMedCentral

83.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. Jama. 2020;323:1061. https://doi.org/10.1001/jama.2020.1585.CrossRefPubMedCentralPubMed

84.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

85.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368:m1091. https://doi.org/10.1136/bmj.m1091.CrossRefPubMedPubMedCentral

86.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–60. https://doi.org/10.1038/s41569-020-0360-5.CrossRefPubMed

87.

Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020. https://doi.org/10.1016/j.bbi.2020.04.077.

88.

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382:e60. https://doi.org/10.1056/NEJMc2009787.CrossRefPubMed

89.

• Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology. 2020. https://doi.org/10.1001/jamaneurol.2020.1127The first cohort study focused on neurologic clinical manifestations of COVID-19.

90.

UK-wide surveillance of neurological and neuropsychiatric complications of COVID-19: the first 153 patients [database on the Internet]2020. Available from: https://ssrn.com/abstract=3601761 Accessed: 29/5/2020.

91.

Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009937.

92.

Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. 2020. https://doi.org/10.1136/jnnp-2020-323586.

93.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38. https://doi.org/10.1056/NEJMc2007575.CrossRefPubMed

94.

Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2018;27(4):572–83. https://doi.org/10.1177/0961203317731532.CrossRefPubMed

95.

Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009848.

96.

Yeboah K, Edgell R, Conway J, Alshekhlee A. Interventional stroke management in a COVID-19 patient. Neurology: Clinical Practice. 2020. https://doi.org/10.1212/CPJ.0000000000000884.

97.

Sharifi-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect. 2020;35:100669. https://doi.org/10.1016/j.nmni.2020.100669.CrossRefPubMedPubMedCentral

98.

Kandemirli SG, Dogan L, Sarikaya ZT, Kara S, Akinci C, Kaya D, Kaya Y, Yildirim D, Tuzuner F, Yildirim MS, Ozluk E, Gucyetmez B, Karaarslan E, Koyluoglu I, Demirel Kaya HS, Mammadov O, Kisa Ozdemir I, Afsar N, Citci Yalcinkaya B, Rasimoglu S, Guduk DE, Kedir Jima A, Ilksoz A, Ersoz V, Yonca Eren M, Celtik N, Arslan S, Korkmazer B, Dincer SS, Gulek E, Dikmen I, Yazici M, Unsal S, Ljama T, Demirel I, Ayyıldız A, Kesimci I, Bolsoy Deveci S, Tutuncu M, Kizilkilic O, Telci L, Zengin R, Dincer A, Akinci IO, Kocer N Brain MRI findings in patients in the intensive care unit with COVID-19 infection. Radiology. 2020;201697. https://doi.org/10.1148/radiol.2020201697.

99.

Brun G, Hak J-F, Coze S, Kaphan E, Carvelli J, Girard N, et al. COVID-19—white matter and globus pallidum lesions. Demyelination or small-vessel vasculitis? Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e777. https://doi.org/10.1212/nxi.0000000000000777.CrossRefPubMedPubMedCentral

100.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. https://doi.org/10.1016/S0140-6736(20)30211-7.CrossRefPubMedPubMedCentral

101.

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMed

102.

Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, et al. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol(R) Neuroimmunol Neuroinflammation. 2020;7(4):e753. https://doi.org/10.1212/NXI.0000000000000753.CrossRef

103.

Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009700.

104.

Min J, Qiaoxia T. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Disease J. 2020;26(7):1618–20. https://doi.org/10.3201/eid2607.200445.CrossRef

105.

Yin R, Feng W, Wang T, Chen G, Wu T, Chen D, et al. Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. J Med Virol. 2020. https://doi.org/10.1002/jmv.25888.

106.

Goh Y, Beh DLL, Makmur A, Somani J, Chan ACY. Pearls and Oy-sters: facial nerve palsy as a neurological manifestation of Covid-19 infection. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009863.

107.

Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus. 2020;12(3):e7352. https://doi.org/10.7759/cureus.7352.CrossRefPubMedPubMedCentral

108.

Herman C, Mayer K, Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology. 2020:10.1212/WNL.0000000000009673. https://doi.org/10.1212/WNL.0000000000009673.

109.

• Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 Infection. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2008597The first European observational series on neurologic features of COVID-19 patients admitted to intensive care units.

110.

Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34–9. https://doi.org/10.1016/j.bbi.2020.04.027.CrossRefPubMedPubMedCentral

111.

Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176. https://doi.org/10.1186/s13054-020-02882-x.CrossRefPubMedPubMedCentral

112.

Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, et al. Two patients with acute meningo-encephalitis concomitant to SARS-CoV-2 infection. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14298.

113.

Rábano-Suárez P, Bermejo-Guerrero L, Méndez-Guerrero A, Parra-Serrano J, Toledo-Alfocea D, Sánchez-Tejerina D, et al. Generalized myoclonus in COVID-19. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009829.

114.

Somani S, Pati S, Gaston T, Chitlangia A, Agnihotri S. De novo status epilepticus in patients with COVID-19. Ann Clin Transl Neurol. 2020. https://doi.org/10.1002/acn3.51071.

115.

Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia. 2020;61:e49–53. https://doi.org/10.1111/epi.16524.CrossRefPubMed

116.

Karimi N, Razavi A, Rouhani N. Frequent convulsive seizures in an adult patient with COVID-19: a case report. Iran Red Crescent Med J. 2020;In Press. https://doi.org/10.5812/ircmj.102828.

117.

Gutierrez-Ortiz C, Mendez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Manas R, et al. Miller fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020:10.1212/WNL.0000000000009619. https://doi.org/10.1212/WNL.0000000000009619.

118.

Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P et al. Guillain-Barre syndrome related to COVID-19 infection. Neurol(R) Neuroimmunol Neuroinflammation. 2020;7(4). https://doi.org/10.1212/NXI.0000000000000741.

119.

Marta-Enguita J, Rubio-Baines I, Gaston-Zubimendi I. Fatal Guillain-Barre syndrome after infection with SARS-CoV-2. Neurologia. 2020;35:265–7. https://doi.org/10.1016/j.nrl.2020.04.004.CrossRefPubMedPubMedCentral

120.

Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, et al. Guillain-Barre syndrome following COVID-19: new infection, old complication? J Neurol. 2020;267:1877–9. https://doi.org/10.1007/s00415-020-09849-6.CrossRefPubMedPubMedCentral

121.

Ebrahimzadeh SA, Ghoreishi A, Rahimian N. Guillain-Barré syndrome associated with the coronavirus disease 2019 (COVID-19). Neurology: Clinical Practice. 2020. https://doi.org/10.1212/CPJ.0000000000000879.

122.

Chan M, Han SC, Kelly S, Tamimi M, Giglio B, Lewis A. A case series of Guillain-Barré syndrome following Covid-19 infection in New York. Neurology: Clinical Practice. 2020. https://doi.org/10.1212/CPJ.0000000000000880.

123.

Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurology - Neuroimmunology Neuroinflammation. 2020;7(5):e785. https://doi.org/10.1212/nxi.0000000000000785.CrossRef

124.

Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–4. https://doi.org/10.1016/S1474-4422(20)30109-5.CrossRefPubMedPubMedCentral

Title: Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses
Authors: Eleni Gavriilaki
Panagiota Anyfanti
Maria Gavriilaki
Antonios Lazaridis
Stella Douma
Eugenia Gkaliagkousi
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Coronavirus
SARS-CoV-2
Thrombotic Microangiopathy
COVID-19
Thrombosis
Published in: Current Hypertension Reports / Issue 9/2020
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-020-01078-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2020

ENaC in Salt-Sensitive Hypertension: Kidney and Beyond

Is Sex a Determinant of COVID-19 Infection? Truth or Myth?

Clinical Decision Support for the Diagnosis and Management of Adult and Pediatric Hypertension

Efficacy of Probiotics in Patients of Cardiovascular Disease Risk: a Systematic Review and Meta-analysis

Tobacco Smoke and Endothelial Dysfunction: Role of Aldehydes?

Hypertension During Pregnancy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials